Heron Therapeutics (NASDAQ:HRTX) Stock Price Passes Above 200-Day Moving Average - Should You Sell?

Heron Therapeutics, Inc. (NASDAQ:HRTX - Get Free Report)'s stock price passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $1.78 and traded as high as $2.20. Heron Therapeutics shares last traded at $2.15, with a volume of 1,147,607 shares changing hands.

Analysts Set New Price Targets

HRTX has been the topic of several analyst reports. Needham & Company LLC reaffirmed a "buy" rating and set a $4.00 price target on shares of Heron Therapeutics in a research note on Friday, April 11th. StockNews.com cut shares of Heron Therapeutics from a "buy" rating to a "hold" rating in a research note on Saturday, March 8th.

Heron Therapeutics Trading Up 11.4 %

The company has a market capitalization of $327.51 million, a price-to-earnings ratio of -11.94 and a beta of 1.39. The stock has a 50-day simple moving average of $2.09 and a 200-day simple moving average of $1.78.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.05. The firm had revenue of $40.78 million for the quarter, compared to analyst estimates of $37.37 million. On average, research analysts forecast that Heron Therapeutics, Inc. will post -0.13 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of HRTX. Barclays PLC increased its position in shares of Heron Therapeutics by 29.8% in the third quarter. Barclays PLC now owns 218,455 shares of the biotechnology company's stock worth $434,000 after acquiring an additional 50,109 shares in the last quarter. Principal Financial Group Inc. grew its position in Heron Therapeutics by 456.5% during the 3rd quarter. Principal Financial Group Inc. now owns 102,651 shares of the biotechnology company's stock worth $204,000 after purchasing an additional 84,205 shares in the last quarter. JPMorgan Chase & Co. raised its stake in Heron Therapeutics by 295.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 206,711 shares of the biotechnology company's stock valued at $411,000 after purchasing an additional 154,487 shares during the period. Congress Park Capital LLC lifted its holdings in shares of Heron Therapeutics by 24.1% in the fourth quarter. Congress Park Capital LLC now owns 2,455,495 shares of the biotechnology company's stock valued at $3,757,000 after purchasing an additional 477,417 shares in the last quarter. Finally, Arkadios Wealth Advisors acquired a new stake in shares of Heron Therapeutics in the fourth quarter worth $76,000. Institutional investors own 80.01% of the company's stock.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.